Comparison of Two Formulations of Biphasic Insulin Aspart 70

• Status: Completed
• Trial end date: 1999-11-30
• Target enrollment: 0
• Participant gender: Male

Summary

This trial is conducted in Europe. The aim of this trial is to compare two formulations of biphasic insulin aspart 70 and characterise the pharmacokinetics of biphasic insulin aspart 50 and biphasic insulin aspart 70 in healthy male subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Biphasic Insulins; Insulin; Insulin Aspart; Insulin degludec, insulin aspart drug combination; Insulin, Globin Zinc; Insulin, Long-Acting

Criteria

Inclusion Criteria:

• Caucasian

• Considered generally healthy upon completion of medical history and physical examination as judged by the Investigator

• Body mass index (BMI) between 19-27 kg/m^2

• Fasting plasma glucose between 3.8-6.0 mmol/L

Exclusion Criteria:

• Participation in any other clinical trial involving other investigational products within the last three months

• Clinically significant abnormal haematology or biochemistry screening tests, as judged by the Investigator

• Any serious systemic infectious disease that occurred in the 4 weeks prior to the first dose of test drug